目的:肢端肥大症与氧化应激和炎症参数相关。壳聚糖三糖苷酶(CHITO)是巨噬细胞活化的标志物,在炎症和免疫反应的活化中起关键作用。我们的研究旨在确定CHITO,YKL-40,糖基化终产物(AGE),高敏C反应蛋白(hsCRP)水平检测丙二醛(MDA),过氧化氢酶,超氧化物歧化酶(SOD),和谷胱甘肽过氧化物酶(GSH-Px)活性,并评估这些参数与控制肢端肥大症患者颈动脉内膜中层厚度(cIMT)的任何关联。
方法:研究了30例肢端肥大症患者和41例年龄和性别匹配的对照病例。我们获得了人口统计数据,荷尔蒙和代谢参数,和cIMT。用Chamoles等人的荧光法测量CHITO活性。使用ELISA测量YKL-40和hsCRP水平。基于荧光光谱检测来测量AGEs。通过比色测定法测定GSH-Px活性。MDA,SOD,在溶血过程中测定过氧化氢酶活性。
结果:更高的CHITO,年龄,与对照组相比,在肢端肥大症患者中观察到hsCRP浓度。肢端肥大症组SOD水平无明显增高,而肢端肥大症患者过氧化氢酶活性较低。CHITO的相关性分析,AGEs,YKL-40,hsCRP,MDA,过氧化氢酶,GSH-Px,和SOD代谢,人体测量学,和实验室参数没有显着相关性(p>0.05)。两组之间的cIMT水平没有显着差异。
结论:这是首次研究肢端肥大症患者的CHITO和AGE水平。血清CHITO,年龄,肢端肥大症患者的hsCRP水平明显升高。评估CHITO可能很重要,年龄,和hsCRP水平在肢端肥大症患者中,这些患者由于发生心血管疾病的风险而已经接受了心脏代谢监测。
OBJECTIVE: Acromegaly is associated with oxidative stress and inflammation parameters. Chitotriosidase (CHITO) is a marker of macrophage activation and plays a pivotal role in the activation of inflammatory and immunological responses. Our study aimed to determine CHITO,YKL-40, advanced glycation end product (AGE), and high-sensitivity C-reactive protein (hsCRP) levels to investigate malondialdehyde (MDA), catalase, superoxide dismutase (SOD), and glutathione peroxidase (GSH-Px) activities and to evaluate any association of these parameters with carotid intima media thickness (cIMT) in patients with controlled acromegaly.
METHODS: Thirty controlled acromegaly patients and 41 age- and sex-matched control cases were studied. We obtained demographic data, hormonal and metabolic parameters, and cIMT. CHITO activity was measured with the fluorometric method of Chamoles et al. YKL-40 and hsCRP levels were measured using ELISA. AGEs were measured based on spectrofluorimetric detection. GSH-Px activity was determined by a colorimetric assay. MDA, SOD, and catalase activities were determined in hemolysis.
RESULTS: Higher CHITO, AGE, and hsCRP concentrations were observed in patients with acromegaly compared to controls. SOD levels were non-significantly higher in the acromegaly group, while catalase activities were lower in patients with acromegaly. Correlation analyses of CHITO, AGEs, YKL-40, hsCRP, MDA, catalase, GSH-Px, and SOD with metabolic, anthropometric, and laboratory parameters did not demonstrate any significant correlation (p > 0.05). There was no significant difference between groups with regard to cIMT levels.
CONCLUSIONS: This is the first study investigating CHITO and AGE levels in patients with acromegaly. Serum CHITO, AGE, and hsCRP levels in acromegalic patients were significantly increased. It may be important to evaluate CHITO, AGE, and hsCRP levels in acromegalic patients who are already under cardiometabolic surveillance due to risk of developing cardiovascular disease.